Strategies for reducing the cost of GLP-1 therapy: insurance maximization, manufacturer programs, cash-pay compounded paths, and the tradeoffs of each.

If you have insurance

  1. Verify GLP-1 coverage with member services — get the formulary tier and PA criteria in writing.
  2. If covered for T2D: pursue Ozempic or Mounjaro through your insurance.
  3. If covered for weight: pursue Wegovy or Zepbound through PA.
  4. If covered for CV indication (BMI ≥27 + established CVD): Wegovy under March 2024 indication.
  5. If covered for OSA (BMI ≥30 + moderate-to-severe OSA): Zepbound under December 2024 indication.
  6. Use a manufacturer copay card if commercial: NovoCare Connect for Wegovy/Ozempic, Lilly Cares for Mounjaro/Zepbound.

If you don't have insurance coverage

  1. Manufacturer cash-pay programs: NovoCare Wegovy cash-pay $499/mo; Lilly Direct Zepbound vial from $349/mo.
  2. Cash-pay compounded: the lowest all-in monthly figure per program in our price table ran $39–$249 (semaglutide) and $86–$299 (tirzepatide) on reads of October 15 and November 6, 2026. It usually costs far less per year than brand self-pay, but compounded drugs are not FDA-approved.
  3. Manufacturer patient assistance: Income-qualified patients may access medication free or reduced-cost. Apply directly to manufacturer.
  4. Clinical trials: Active GLP-1 trials provide medication free during trial period. Check clinicaltrials.gov.

If your plan excludes weight-management drugs

  1. Check eligibility for non-weight indications you may qualify for (CV for Wegovy; OSA for Zepbound; T2D if newly diagnosed).
  2. Discuss with your employer's HR or benefits team — many large employers are reviewing weight-management coverage given the SELECT and SURMOUNT-OSA findings.
  3. Appeal denials with detailed medical-necessity documentation.
  4. Cash-pay compounded as an alternative path.

HSA and FSA

GLP-1 medications are HSA/FSA-eligible when prescribed for a medical indication. This includes both branded and compounded medications. Use pre-tax dollars where you can.

Tax considerations

Medical expenses exceeding 7.5% of AGI are tax-deductible. For high-cost GLP-1 paths (e.g., cash-pay branded Wegovy), this can be material.

Travel medication considerations

Some patients save by sourcing branded GLP-1 in countries with lower drug pricing. This carries import legality risks and supply chain risks. Not recommended; cash-pay compounded U.S. programs are generally a better path.

What we don't recommend

Researched By Dr. Parmis · Medical Researcher · Western University of Health Sciences

Medically Reviewed By Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: · This page is informational and does not constitute medical advice.